



30  
Petitioner's Docket No. MPI99-017DV1AM

1652  
**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of:	Martin R. Hodge, et al.		
Application No.:	09/894,749	Group No.:	1652
Filed:	June 27, 2001	Examiner:	N/A
For:	NOVEL RGS-CONTAINING MOLECULES AND USES THEREOF		

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed:

☒ Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

**OR**

☐ *After* three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

☒ deposited with the United States Postal Service in an envelope addressed to the Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_

**TRANSMISSION**

☐ transmitted by facsimile to the Patent and Trademark Office.

Diana Gentile  
Signature

Date: August 27, 2003

Diana Gentile  
(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Practitioner's Docket No. MPI99-017DV1AM**

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

☐ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

☐ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

**OR**

☐ The information disclosure statement transmitted herewith is being filed *after* a final action under Section 1.113, or a notice of allowance under Section 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.

☐ In accordance with the requirements of 37 C.F.R. Section 1.97(d):

A. ☐ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

B. ☐ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

C. ☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

Practitioner's Docket No. MPI99-017DV1AM

**FEE PAYMENT**


3. ☐ The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).


☒ Applicant believes no fee is due in connection with this submission.

	Fee due	\$0.00
<b>METHOD OF PAYMENT OF FEE</b>		
4. <input type="checkbox"/> Attached is a check in the amount of \$ _____.		
<input type="checkbox"/> Charge Account No. 501668 in the amount of	\$0.00	.

☐ A duplicate of this request is attached.

If any additional fees are due, please charge Account 501668.

<u>August 27, 2003</u>	MILLENNIUM PHARMACEUTICALS, INC. By <u></u> Kerri Pollard Schray Registration No. 47,066 75 Sidney Street Cambridge, MA 02139 Telephone – (617) 551-3676 Facsimile – (617) 551-8820
------------------------	---



Practitioner's Docket No. MPI99-017DV1AM

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Prere application of:	Martin R. Hodge, et al.		
Application No.:	09/894,749	Group No.:	1652
Filed:	June 27, 2001	Examiner:	N/A
For:	NOVEL RGS-CONTAINING MOLECULES AND USES THEREOF		

**Mail Stop DD**  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**List of Sections Forming Part of This Information Disclosure Statement**

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ Form PTO/SB/08B (1 page)
3. ☒ Copies of Listed Information Items Accompanying This Statement (5 references)
4. ☒ Copy of Search Report (2 pages)

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**


**37 C.F.R. SECTION 1.10\***

- ☒ with sufficient postage as first class mail.

- ☐ as "Express Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_

**TRANSMISSION**

- ☐ transmitted by facsimile to the Patent and Trademark Office.

  
\_\_\_\_\_  
**Signature**

Date: August 27, 2003

Diana Gentile  
(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI99-017DV1AM

**Preliminary statements**

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.


**Copies of Listed Information Items Accompanying This Statement**

Legible copies of all items listed in PTO/SB/08B (substitute for Form PTO-1449) accompany this information statement.

August 27, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By:



Kerri Pollard Schray  
Registration No. 47,066  
75 Sidney Street  
Cambridge, MA 02139  
Telephone – (617) 551-3676  
Facsimile – (617) 551-8820

Please type a plus sign (+) inside this box →




PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitut for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				Application Number	09/894,749
				Filing Date	June 27, 2001
				First Named Inventor	Martin R. Hodge, et al.
				Group Art Unit	1652
				Examiner Name	N/A
Sheet	1	of	1	Attorney Docket Number	MPI99-017DV1M

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T <sup>2</sup>
	21	Database SWISSPROT 'online! 15 December 1998 (1998-12-15) "Regulator of G-Protein Signaling 5 (RGS5): Database Accession No. 015539 XP002241842 *whole document"	
	22	Database SWISSPROT 'online! 1 February 1995 (1995-02-01) "Regulator of G-Protein Signaling 2 (RGS2) (GO/G1 Switch Regulatory Protein 8)," Database Accession No. P41220 XP002241843 *whole document"	
	23	Database EMBL 'online! EBI; 23 December 1998 (1998-12-23) Adams M.D., et al: "RPC11-104A6. TJ RPCI-11 Homo Sapiens Genomic Clone RPCI-11-104A6, Genomic Survey Sequence," Database Accession No. AQ317367 XP002241844, see sequence	
	24	Park, InKyung et al., "Molecular Cloning and Characterization of a novel Regulator of G-Protein Signaling from Mouse Hematopoietic Stem Cells", Journal of Biological Chemistry Vol. 276, No. 2, (12 January 2001), pp. 915-923, XP002188252, ISSN: 0021-9258	
	25	Yowe, David et al., "RGS18 is a Myeloerythroid Lineage-specific Regulator of G-Protein-Signalling Molecule Highly Expressed in Megakaryocytes", Biochemical Journal Vol. 359, No. 1, (2001), pp. 109-118, XP002188250, ISSN: 0264-6021	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here is English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.